English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In their 2006 annual data report, the USRDS reported that after years of considerable growth, the rate of new patients taken into renal replacement therapy (RRT) has begun to decrease slightly. Between 2002 and 2004, the overall incidence rate adjusted for age and sex declined by 1.1% to reach 339 per million population (pmp). This decline included a reduction in the incidence rate of RRT for diabetic ESRD of 2.1% to 149 pmp, over the same period. While the incidence rate in the white population had not changed since 2002, there was a decrease in the black, Native American and Asian patients of 4.0%, 5.5% and 8%, respectively [1]. However, subgroup analysis showed that the US incidence rates had decreased in females, but not in males. Furthermore, the continuing rise in diabetic ESRD rates for black patients, aged 30–39 years remained a cause for concern. Nevertheless, the data suggested at least a stabilization of the RRT incidence rate in the US and this is an observation of great interest. Indeed, until recently, many researchers predicted a continuing rise in the RRT incidence rate of as high as 5–8% per year in the more developed countries [2,3].

Has the rise in the incidence of renal replacement therapy in developed countries come to an end?